News, Insights, & Events

Insights
Entrada Case Study

See SmartLabs in Action!

Insights
Gritstone Case Study

See SmartLabs in Action!

Events
Next Generation CAR & T Cell Therapies

Revolutionizing cell and gene engineering - ground breaking autologous and allogeneic treatments for blood borne and solid tumors

#ef9146
Member News
Orna Therapeutics Announces First-in-Class, Breakthrough Data Demonstrating Potential of Circular RNA Platform at ASGCT 2022

- Advances in oRNA expression and delivery enable pipeline of therapeutics across a diverse range of disease areas

- Lead is CAR program shows possibility of tumor eradication in preclinical animal models with promise of translation to non-human primates and patients

#e28869
Member News
2022 Category Winner for Innovation: CRISPR Therapeutics

The FOYA judging committee commends CRISPR for creating a flexible, digitally-enabled facility that can bring the promise of innovation to life.

#e28869
Member News
Cue Biopharma Receives FDA Acceptance of Investigational New Drug (IND) Application for CUE-102 in Wilms’ Tumor 1 (WT1) - expressing cancers

- Company to initiate Phase 1 dose escalation and expansion trial for the treatment of Wilms’ Tumor 1 (WT1) positive recurrent/metastatic cancers

- Starting dose of 1 mg/kg expected to reduce time and cost of dose escalation phase of trial, supporting development efficiency of CUE-100 series platform

#e28869
Events
ASGCT 25th Annual Meeting

Originally designed as a venue for academic researchers to share their work, the Annual Meeting has grown to serve a wide community encompassing clinicians, bio-industry development, regulatory agencies, equipment manufacturers, patient advocates, and more.

#ef9146
Member News
Solid Biosciences Announces Updated Corporate Strategy to Develop SGT-001 and SGT-003 Pipeline Programs for Patients with Duchenne Muscular Dystrophy

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced an update to its strategic priorities to focus on developing SGT-001 and SGT-003. The company also announced financial results for the first quarter ended March 31, 2022.

#e28869
Member News
Editas sees clinical promise with new FDA pediatric disease tag for another blood disorder

Following a management shake-up, Editas Medicine received some welcome good news. The biotech has scored a second rare pediatric disease designation from the FDA for its gene edited medicine EDIT-301.

#e28869
Events
Cell & Gene Meeting On The Med

The Cell & Gene Meeting on the Mediterranean is the leading conference bringing together the entire cell and gene therapy community from Europe and beyond.

#ef9146
Insights
SmartLabs Brochure

Learn More About How Are We Building Labs That Today's Science Deserves 

Member News
Be Bio uses Arch Venture-led $130M financing round to harness 'power of the B cell'

Move over, A: B is taking the lead now, with Be Biopharma closing out a $130 million financing round backed by several industry leaders that will fuel its engineered B cells platform.

#e28869